Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

35.43

Mkt cap

231B

Volume

149K

High

35.43

P/E Ratio

18.91

52-wk high

42.43

Low

35.17

Div yield

0.04

52-wk low

29.20

Roche's Phase IIb study of prasinezumab, conducted in partnership with Prothena, did not meet its primary endpoint but indicated potential clinical benefits for early-stage Parkinson's disease patients.

Portfolio Pulse from

December 19, 2024 | 6:30 am

Genentech's Phase IIb study of prasinezumab in early-stage Parkinson's disease did not meet its primary endpoint but showed potential benefits. The study involved 586 participants over 18 months.

Portfolio Pulse from

December 19, 2024 | 6:15 am

Roche's Phase IIb study of prasinezumab for early-stage Parkinson's disease did not meet its primary endpoint but showed potential benefits, especially in patients treated with levodopa. The drug was well tolerated with no new safety concerns.

Portfolio Pulse from

December 19, 2024 | 6:15 am

Roche has received EU approval for its ophthalmology drug Vabysmo in a prefilled syringe form, targeting three retinal diseases that can lead to blindness.

Portfolio Pulse from

December 16, 2024 | 8:00 pm

Roche has received CE Mark certification for its updated cobas 6800/8800 systems, which enhance laboratory efficiency and testing capabilities. The improvements include optimized resources, reduced downtime, consolidated test menus, and increased throughput, benefiting healthcare professionals and patients.

Portfolio Pulse from

December 13, 2024 | 6:15 am

Roche presented new data at the ASH 2024 meeting, highlighting the potential of its bispecific antibodies, Columvi and Lunsumio, to improve lymphoma treatment outcomes. The data supports Roche's innovation in advancing treatment standards and exploring new administration methods.

Portfolio Pulse from

December 10, 2024 | 6:15 am

Roche has initiated a tender offer to acquire all shares of Poseida Therapeutics for $9.00 per share in cash, with an additional contingent value right of up to $4.00 per share. This follows a merger agreement announced on November 25, 2024.

Portfolio Pulse from

December 09, 2024 | 9:45 pm

The FDA has accepted Roche's supplemental Biologics License Application (sBLA) for Columvi, aiming to expand its use for treating second-line relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Portfolio Pulse from

December 05, 2024 | 2:45 pm

The FDA has accepted Roche's supplemental Biologics License Application for Columvi in combination with GemOx for treating relapsed or refractory diffuse large B-cell lymphoma. A decision is expected by July 2025.

Portfolio Pulse from

December 05, 2024 | 6:15 am

Roche is acquiring Poseida Therapeutics for $1.5 billion to enhance its pipeline with CAR-T cell therapies.

Portfolio Pulse from

November 26, 2024 | 5:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.